Our hybrid business model comprises the development, manufacture and commercialization of products targeted against large treatment markets that are currently underserved and the provision of state-of-the-art Contract Development and Manufacturing services to global companies by means of our CDMO division,
Our products include differentiated biosimilars, novel biologics and other complex large molecules. Stelis operates research, development and cGMP manufacturing out of Bangalore, India with the aim of bringing world-class treatments at affordable cost to patients in both emerging and developed markets.
